According to a recent market study published by Growth Market Reports titled, “Global Acromegaly Treatment Market by Product, End-user, and Region: Size, Share, Trends and Opportunity Analysis, 2017-2027”, the market was valued at USD 1,304.4 Million in 2019 and is expected to grow at a healthy growth rate of 7.6% by the year 2027. The global acromegaly treatment market is anticipated to grow owing to rising prevalence of acromegaly especially in developed countries. Further, increasing awareness among the people for acromegaly, and rising number of clinical trials for acromegaly drugs are the factors which is expected to drive the growth of the global acromegaly treatment market.

The global acromegaly treatment market is fragmented based on product, end-user, and region. In terms of product, the market is segmented into somatostatin analogs, growth hormone receptor antagonist (GHRA), and dopamine agonist. On the basis of end-user, the market is divided into hospitals & clinics, and others. Based on region, the global acromegaly treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, Asia Pacific is further segmented into, China, Japan, South Korea, Australia, Southeast Asia, and Rest of Asia Pacific. The Europe region is further categorized into Germany, France, Italy, U.K., Spain, Russia, and Rest of Europe, and the MEA region is further divided into Saudi Arabia, South Africa, UAE, and Rest of MEA.

Request a free sample copy: https://growthmarketreports.com/request-sample/17

Acromegaly is one the rare disorders which is usually caused by excess development of growth hormone by the pituitary gland. This excessive growth hormone affects a patient’s internal organs and physical appearance. Acromegaly is mainly caused by benign pituitary tumor (adenoma); however, in rare cases acromegaly is caused by ineffective control of GH-secreting cells by hypothalamus. If acromegaly is untreated or not treated properly, it can lead to serious and life threating complication such as ventricular arrythmia and cardiomyopathy. To detect acromegaly doctor’s use diagnostic approaches such as blood test to measure the level of insulin-like growth factor or growth hormones and imaging of tumor through computed tomography (CT) scan and magnetic resonance image (MRI) scan. In acromegaly treatment some of the medications which are used are 90% effective in shrinking the tumor. However, the success rate for acromegaly treatment varies health, age, and medical history of the patient. 

As per Growth Market Reports industry analyst Vidya Jadhav, “The Global Acromegaly Treatment Market is anticipated to witness significant growth during forecast period 2021-2027 driven by increasing prevalence and incidence of acromegaly across globe, rising awareness across developing economies, increasing initiatives taken by government to promote the awareness about this rear disease. Moreover, the increasing R&D, investments, and boom in clinical trials to develop new medication for acromegaly is expected to create lucrative opportunity during forecast period.”

Key Takeaways from the Study:

  • France based Ipsen Pharma, holds approximately one fourth of the market share of global acromegaly treatment market in year 2019.

  • U.S. accounts for a major share of the market, followed by Europe. The market in Asia Pacific is projected to expand at significant CAGR during the forecast period.

  •  In terms of value, the hospital & clinic segment is anticipated to expand at a significant CAGR during the forecast period. Large number of surgeries and diagnostic producers are performed in hospitals & clinics. Furthermore, factor such as availability surgeons and advance diagnostics facilities is contributing to the large market share of the segment. This, in turn, creates awareness among the people about the acromegaly treatment, thus boosting segment growth.

  • The somatostatin analogs segment is anticipated to expand at a substantial CAGR during the forecast period due to growing preference for somatostatin analogs by healthcare professionals and due to strong pipeline of drugs in the market. The segment is expected to dominate the market throughout forecast period with more than 70% of share.

Report Scope:

Report Metric

Details

Market Value in 2019

USD 1,304.4 Million

Market Growth Rate (from 2021 to 2027)

7.6 %

Historical Data

2017 & 2018

Base Year

2019

Forecast Period

2020 - 2027

Units Considered

Value (USD Million)

Market Segments

By Product, By End-users

Regional Scope

North America, Europe, Latin America, Asia Pacific, Middle East & Africa (MEA)

Country Scope

U.S., Canada, Brazil, Mexico, Rest of Latin America, China, Japan, South Korea, India, Australia, Southeast Asia, Rest of Asia Pacific, Germany, France, Italy, U.K., Spain, Russia, Rest of Europe, Saudi Arabia, South Africa, UAE, and Rest of MEA.

Key Companies Profiled

Novartis AG, Sun Pharmaceutical Industries Ltd., DAEWOONG PHARMACEUTICAL CO.,LTD., Ispen Pharma, Pfizer Inc., Dauntless Pharmaceuticals, and WOCKHARDT

Pipeline Analysis (Companies Profiled)

Chiasma Inc., Enesi, Peptron, Strongbridge Biopharma plc, Ionis Pharmaceuticals, Inc., Aquestive Therapeutics, Inc., Amryt Pharma plc, and Foresee Pharmaceuticals Co., Ltd.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail tailor-made purchase options to meet your research requirements.

 

Target Audience:

  • Supply-side: Acromegaly drugs and injections manufacturers (Pharmaceutical Companies), raw material suppliers, primary respondents, and distributors.

  • Demand Side: Hospitals, Clinics, Homecare, Pharmacies, Drug stores, Group Purchasing Organizations, Medical payers etc.

  • Regulatory Side: Concerned government authorities, commercial research & development (R&D) institutions, and other regulatory bodies

  • Associations and Industry Bodies: Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), World Health Organization (WHO), Medicines and Healthcare Products Regulatory Agency (MHRA), Therapeutic Goods Administration (TGA), Central Drug Standard Control Organization (CDSCO), American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), European Medicines Agency (EMA), International Federation of Pharmaceutical Manufacturers & Association (IFPMA), World Trade Organization (WTO), Indian Medical Research Council (ICMR).